Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics

Executive Summary

AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.

Advertisement

Related Content

AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors
BI Bets On Expanding Jardiance As Diabetes Drug Sales Soar
AZ's Forxiga Gets Type 1 Diabetes EU Okay As Sanofi Suffers US Setback
First Approval For AZ's Roxadustat With China Green Light
AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel